News | August 16, 2021
Glenmark Pharmaceuticals net profit at Rs 306.52 crores in Q1FY22
The company reports revenue growth of 26% and PAT growth of 21% YoY
The company reports revenue growth of 26% and PAT growth of 21% YoY
Fitterfly has launched an online Prediabetes risk test which is an evidence-based, clinically validated tool for assessing an individual's risk of Prediabetes
It falls under the Department of Biotechnology - Mission Covid Suraksha Project for augmenting manufacturing capacity for Covaxin
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
The company is eligible for 12 months exclusivity from launch
The company has strong product launches both in India and overseas
Demand normalisation post the second wave contributed to the steady growth
Wastewater surveillance is becoming increasingly critical for community health monitoring for detecting COVID-19 outbreaks and the spread of other infectious diseases
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
Subscribe To Our Newsletter & Stay Updated
